Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...
Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts
Biogen Inc (NASDAQ:BIIB) reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company ...
Is The Alzheimer’s Drug Leqembi Covered By Medicare?
Progressive and incurable, Alzheimer’s disease affects an estimated 6.7 million U.S. adults at least 65 years old, according ...
Biogen targets $15.25-$16.25 EPS for 2025 amid LEQEMBI growth and cost savings
Q4 2024 Management View Chris Viehbacher, CEO, noted that Biogen is focused on three core priorities: driving growth from its four recently launched products, reprioritizing the pipeline for ...
BioSpace2d
With Leqembi Sales Trending Up, Biogen Gets Down to Brass Tacks: It Works
Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...
FiercePharma3d
Eisai execs flag Leqembi 'expansion phase' on the horizon as Alzheimer's med grows slowly
Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...
Biogen's 2025 forecasts hit by declining sales for MS drugs, strong dollar
Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for ...
NBC Washington3d
Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth.